EHC vs. REGN: A Head-to-Head Stock Comparison
Updated onHere’s a clear look at EHC and REGN, comparing key factors like historical performance, profitability, financial strength, growth, dividend, and valuation.
Company Profile
| Symbol | EHC | REGN |
|---|---|---|
| Company Name | Encompass Health Corporation | Regeneron Pharmaceuticals, Inc. |
| Country | United States | United States |
| GICS Sector | Health Care | Health Care |
| GICS Industry | Health Care Providers & Services | Biotechnology |
| Market Capitalization | 12.00 billion USD | 59.52 billion USD |
| Exchange | NYSE | NasdaqGS |
| Listing Date | September 24, 1986 | April 2, 1991 |
| Security Type | Common Stock | Common Stock |
Historical Performance
This chart compares the performance of EHC and REGN by tracking the growth of an initial $10,000 investment in each. Use the tabs to select the desired time period. Data is adjusted for dividends and splits.
Historical Performance at a Glance
| Symbol | EHC | REGN |
|---|---|---|
| 5-Day Price Return | 2.25% | 0.31% |
| 13-Week Price Return | 1.88% | -2.45% |
| 26-Week Price Return | 20.82% | -22.23% |
| 52-Week Price Return | 37.15% | -49.91% |
| Month-to-Date Return | 8.19% | 2.95% |
| Year-to-Date Return | 29.00% | -21.17% |
| 10-Day Avg. Volume | 1.09M | 1.11M |
| 3-Month Avg. Volume | 0.92M | 1.23M |
| 3-Month Volatility | 26.29% | 49.41% |
| Beta | 0.96 | 0.31 |
Profitability
Return on Equity (TTM)
EHC
24.70%
Health Care Providers & Services Industry
- Max
- 26.03%
- Q3
- 13.74%
- Median
- 8.26%
- Q1
- 4.13%
- Min
- -3.62%
In the upper quartile for the Health Care Providers & Services industry, EHC’s Return on Equity of 24.70% signals a highly effective use of shareholder capital to drive profitability compared to most of its peers.
REGN
15.11%
Biotechnology Industry
- Max
- 77.14%
- Q3
- 10.76%
- Median
- -20.08%
- Q1
- -42.71%
- Min
- -119.20%
In the upper quartile for the Biotechnology industry, REGN’s Return on Equity of 15.11% signals a highly effective use of shareholder capital to drive profitability compared to most of its peers.
Net Profit Margin (TTM)
EHC
9.22%
Health Care Providers & Services Industry
- Max
- 12.40%
- Q3
- 5.93%
- Median
- 1.96%
- Q1
- 0.93%
- Min
- -6.10%
A Net Profit Margin of 9.22% places EHC in the upper quartile for the Health Care Providers & Services industry, signifying strong profitability and more effective cost management than most of its peers.
REGN
31.37%
Biotechnology Industry
- Max
- 59.44%
- Q3
- 16.21%
- Median
- -11.49%
- Q1
- -167.42%
- Min
- -409.07%
A Net Profit Margin of 31.37% places REGN in the upper quartile for the Biotechnology industry, signifying strong profitability and more effective cost management than most of its peers.
Operating Profit Margin (TTM)
EHC
17.06%
Health Care Providers & Services Industry
- Max
- 19.05%
- Q3
- 10.21%
- Median
- 4.22%
- Q1
- 1.98%
- Min
- -4.27%
An Operating Profit Margin of 17.06% places EHC in the upper quartile for the Health Care Providers & Services industry. This signals a strong ability to translate revenue into operating profit, outperforming most of its competitors in core business efficiency.
REGN
27.02%
Biotechnology Industry
- Max
- 60.62%
- Q3
- 20.76%
- Median
- -12.41%
- Q1
- -181.14%
- Min
- -482.02%
An Operating Profit Margin of 27.02% places REGN in the upper quartile for the Biotechnology industry. This signals a strong ability to translate revenue into operating profit, outperforming most of its competitors in core business efficiency.
Profitability at a Glance
| Symbol | EHC | REGN |
|---|---|---|
| Return on Equity (TTM) | 24.70% | 15.11% |
| Return on Assets (TTM) | 7.91% | 11.81% |
| Net Profit Margin (TTM) | 9.22% | 31.37% |
| Operating Profit Margin (TTM) | 17.06% | 27.02% |
| Gross Profit Margin (TTM) | 95.62% | 86.46% |
Financial Strength
Current Ratio (MRQ)
EHC
1.06
Health Care Providers & Services Industry
- Max
- 2.01
- Q3
- 1.49
- Median
- 1.30
- Q1
- 0.94
- Min
- 0.17
EHC’s Current Ratio of 1.06 aligns with the median group of the Health Care Providers & Services industry, indicating that its short-term liquidity is in line with its sector peers.
REGN
4.60
Biotechnology Industry
- Max
- 19.31
- Q3
- 9.38
- Median
- 4.54
- Q1
- 2.45
- Min
- 0.76
REGN’s Current Ratio of 4.60 aligns with the median group of the Biotechnology industry, indicating that its short-term liquidity is in line with its sector peers.
Debt-to-Equity Ratio (MRQ)
EHC
1.08
Health Care Providers & Services Industry
- Max
- 2.17
- Q3
- 1.18
- Median
- 0.74
- Q1
- 0.45
- Min
- 0.00
EHC’s Debt-to-Equity Ratio of 1.08 is typical for the Health Care Providers & Services industry, indicating its use of leverage is in line with the sector norm. This suggests a balanced approach to its capital structure.
REGN
0.09
Biotechnology Industry
- Max
- 1.35
- Q3
- 0.64
- Median
- 0.09
- Q1
- 0.00
- Min
- 0.00
REGN’s Debt-to-Equity Ratio of 0.09 is typical for the Biotechnology industry, indicating its use of leverage is in line with the sector norm. This suggests a balanced approach to its capital structure.
Interest Coverage Ratio (TTM)
EHC
6.58
Health Care Providers & Services Industry
- Max
- 14.47
- Q3
- 7.15
- Median
- 5.45
- Q1
- 2.04
- Min
- -4.44
EHC’s Interest Coverage Ratio of 6.58 is positioned comfortably within the norm for the Health Care Providers & Services industry, indicating a standard and healthy capacity to cover its interest payments.
REGN
243.95
Biotechnology Industry
- Max
- 72.37
- Q3
- 1.91
- Median
- -7.81
- Q1
- -63.90
- Min
- -153.80
With an Interest Coverage Ratio of 243.95, REGN demonstrates a superior capacity to service its debt, placing it well above the typical range for the Biotechnology industry. This stems from either robust earnings or a conservative debt load.
Financial Strength at a Glance
| Symbol | EHC | REGN |
|---|---|---|
| Current Ratio (MRQ) | 1.06 | 4.60 |
| Quick Ratio (MRQ) | 0.87 | 3.78 |
| Debt-to-Equity Ratio (MRQ) | 1.08 | 0.09 |
| Interest Coverage Ratio (TTM) | 6.58 | 243.95 |
Growth
Revenue Growth
EPS Growth
Dividend
Dividend Yield (TTM)
EHC
0.56%
Health Care Providers & Services Industry
- Max
- 5.38%
- Q3
- 2.22%
- Median
- 0.55%
- Q1
- 0.00%
- Min
- 0.00%
EHC’s Dividend Yield of 0.56% is consistent with its peers in the Health Care Providers & Services industry, providing a dividend return that is standard for its sector.
REGN
0.00%
Biotechnology Industry
- Max
- 0.00%
- Q3
- 0.00%
- Median
- 0.00%
- Q1
- 0.00%
- Min
- 0.00%
REGN currently does not pay a dividend, resulting in a yield of 0%. This is a common strategy for growth-focused companies that prioritize reinvesting earnings, though it may be less typical in mature, income-oriented sectors.
Dividend Payout Ratio (TTM)
EHC
12.84%
Health Care Providers & Services Industry
- Max
- 186.69%
- Q3
- 74.82%
- Median
- 26.76%
- Q1
- 0.00%
- Min
- 0.00%
EHC’s Dividend Payout Ratio of 12.84% is within the typical range for the Health Care Providers & Services industry, suggesting a balanced approach between shareholder payouts and company reinvestment.
REGN
0.00%
Biotechnology Industry
- Max
- 0.00%
- Q3
- 0.00%
- Median
- 0.00%
- Q1
- 0.00%
- Min
- 0.00%
REGN has a Dividend Payout Ratio of 0%, indicating it does not currently pay a dividend. This is a common strategy for growth-oriented companies that reinvest all profits back into the business.
Dividend at a Glance
| Symbol | EHC | REGN |
|---|---|---|
| Dividend Yield (TTM) | 0.56% | 0.00% |
| Dividend Payout Ratio (TTM) | 12.84% | 0.00% |
Valuation
Price-to-Earnings Ratio (TTM)
EHC
22.92
Health Care Providers & Services Industry
- Max
- 55.89
- Q3
- 30.85
- Median
- 21.17
- Q1
- 12.63
- Min
- 0.00
EHC’s P/E Ratio of 22.92 is within the middle range for the Health Care Providers & Services industry. This suggests its valuation is in line with the sector average, representing neither a significant premium nor a discount compared to its peers.
REGN
13.20
Biotechnology Industry
- Max
- 60.14
- Q3
- 38.17
- Median
- 29.01
- Q1
- 15.12
- Min
- 0.00
In the lower quartile for the Biotechnology industry, REGN’s P/E Ratio of 13.20 suggests the stock may be undervalued compared to its peers, potentially presenting an attractive entry point for investors.
Price-to-Sales Ratio (TTM)
EHC
2.11
Health Care Providers & Services Industry
- Max
- 3.10
- Q3
- 1.74
- Median
- 0.67
- Q1
- 0.24
- Min
- 0.00
EHC’s P/S Ratio of 2.11 is in the upper echelon for the Health Care Providers & Services industry. This means the company is valued richly on its revenue stream compared to its peers, suggesting the stock is priced for a high level of future performance.
REGN
4.14
Biotechnology Industry
- Max
- 76.98
- Q3
- 36.53
- Median
- 9.49
- Q1
- 4.49
- Min
- 0.00
In the lower quartile for the Biotechnology industry, REGN’s P/S Ratio of 4.14 indicates its revenue is valued more conservatively than most of its peers. This could present a compelling opportunity if the market has overlooked its sales-generating capabilities.
Price-to-Book Ratio (MRQ)
EHC
5.43
Health Care Providers & Services Industry
- Max
- 7.61
- Q3
- 4.32
- Median
- 2.53
- Q1
- 1.14
- Min
- 0.77
EHC’s P/B Ratio of 5.43 is in the upper tier for the Health Care Providers & Services industry. This indicates that investors are paying a premium relative to the company’s net assets, a valuation that hinges on its ability to generate superior profits.
REGN
1.89
Biotechnology Industry
- Max
- 20.53
- Q3
- 9.76
- Median
- 4.77
- Q1
- 2.49
- Min
- 0.59
REGN’s P/B Ratio of 1.89 is in the lower quartile for the Biotechnology industry. From a value investing perspective, this is favorable, as it suggests the stock is trading at a discount to its net asset value and may offer a greater margin of safety.
Valuation at a Glance
| Symbol | EHC | REGN |
|---|---|---|
| Price-to-Earnings Ratio (TTM) | 22.92 | 13.20 |
| Price-to-Sales Ratio (TTM) | 2.11 | 4.14 |
| Price-to-Book Ratio (MRQ) | 5.43 | 1.89 |
| Price-to-Free Cash Flow Ratio (TTM) | 27.28 | 16.55 |